Table 3.
An internal dose-response analysis.
| ICD-10 | Site | Digitoxin concentration ng/ml | ||
| <16 | 16–22 | >22 | ||
| C50 | Breast | 1.00 (reference) | 1.04(0.59, 1.84) | 0.90(0.48, 1.67) |
| C61 | Prostate | 1.00 (reference) | 0.79(0.51, 1.22) | 0.89(0.56, 1.40) |
| C18–C21 | Colo-rectal | 1.00 (reference) | 0.97(0.66, 1.42) | 0.92(0.61, 1.40) |
| C32–C34 | Lung | 1.00 (reference) | 1.25(0.71,2.22) | 1.06(0.57,2.00) |
| C64, C65 | Kidney, urinary | 1.00 (reference) | 0.30(0.15,0.57) | 0.45 (0.24, 0.83) |
| C67, C68 | organs | |||
| C43,C44 | Melanoma, other | 1.00 (reference) | 1.16(0.60,2.25) | 1.29(0.65,2.57) |
| skin | ||||
| C81–C85 | Leukemia and | 1.00 (reference) | 0.67(0.38, 1.18) | 0.57(0.30, 1.08) |
| C88–C92 | Lymphoma | |||
| C00-C97 | All sites | 1.00 (reference) | 0.84(0.71,0.99) | 0.86(0.72, 1.02) |
An internal dose-response analysis. Age-adjusted relative risks (95% confidence limits) of specific types of cancer by concentration levels (tertiles) of digitoxin. A Cox regression analysis was used.